Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers Corcoran RB; Settleman J; Engelman JAOncotarget 2011[Apr]; 2 (4): 336-46Recent clinical trials with selective inhibitors of the BRAF and MEK kinases have shown promising results in patients with tumors harboring BRAF V600 mutations. However, as has been observed previously with similarly successful targeted therapies, acquired resistance to these agents is an emerging problem that limits their clinical benefit. Several recent studies from our laboratory and others have investigated the causes of acquired resistance to BRAF and MEK inhibitors, and multiple resistance mechanisms have been identified. Here, we review these mechanisms and suggest that they can be broadly grouped into two main classes: ERK-dependent and ERK-independent. We also propose distinct therapeutic strategies that might be employed to overcome each class of acquired resistance..|Animals[MESH]|Antineoplastic Agents/*therapeutic use[MESH]|Clinical Trials as Topic/methods/trends[MESH]|Drug Resistance, Neoplasm/*drug effects/genetics[MESH]|Humans[MESH]|Mitogen-Activated Protein Kinase Kinases/*antagonists & inhibitors[MESH]|Models, Biological[MESH]|Mutant Proteins/genetics/physiology[MESH]|Neoplasms/*drug therapy[MESH]|Protein Kinase Inhibitors/*therapeutic use[MESH]|Proto-Oncogene Proteins B-raf/*antagonists & inhibitors/genetics/physiology[MESH]|Treatment Failure[MESH] |